We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.52%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
Cap. Flow
-$140M
Cap. Flow %
-5.1%
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$88.4M
2
UTHR icon
United Therapeutics
UTHR
+$54.7M
3
CVS icon
CVS Health
CVS
+$52.7M
4
AVTR icon
Avantor
AVTR
+$43.5M
5
ABBV icon
AbbVie
ABBV
+$41.5M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$60.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$54.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$44.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$42.1M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
51
Phathom Pharmaceuticals
PHAT
$930M
$15.7M 0.57%
1,721,580
+104,280
+6% +$898K
VRNA
52
DELISTED
Verona Pharma
VRNA
$15.5M 0.57%
780,900
-49,400
-6% -$729K
IMNM icon
53
Immunome
IMNM
$2.63B
$14.3M 0.52%
+1,333,479
New +$11.1M
A icon
54
Agilent Technologies
A
$39.7B
$13.8M 0.5%
+99,000
New +$11.8M
NTLA icon
55
Intellia Therapeutics
NTLA
$1.52B
$13.6M 0.5%
447,434
+68,334
+18% +$1.96M
SYRS
56
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13M 0.48%
1,673,538
+92,396
+6% +$316K
DNTH icon
57
Dianthus Therapeutics
DNTH
$5.55B
$12.7M 0.46%
1,217,554
– –
ARGX icon
58
argenx
ARGX
$54.6B
$11.8M 0.43%
31,000
-49,600
-62% -$23.1M
CERE
59
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$11.7M 0.43%
276,888
-366,112
-57% -$10.5M
COLL icon
60
Collegium Pharmaceutical
COLL
$1.16B
$11.1M 0.41%
361,363
+11,163
+3% +$280K
IMVT icon
61
Immunovant
IMVT
$7.99B
$10.3M 0.38%
245,000
-928,662
-79% -$34.2M
NGNE icon
62
Neurogene
NGNE
$663M
$9.04M 0.33%
+466,243
New +$6.68M
TVTX icon
63
Travere Therapeutics
TVTX
$5.2B
$7.43M 0.27%
827,010
-495,990
-37% -$3.61M
KPTI icon
64
Karyopharm Therapeutics
KPTI
$161M
$7.18M 0.26%
553,238
– –
AKRO
65
DELISTED
Akero Therapeutics
AKRO
$5.49M 0.2%
235,000
-504,100
-68% -$9.94M
KZR
66
DELISTED
Kezar Life Sciences
KZR
$4.76M 0.17%
502,545
-98,565
-16% -$866K
IPSC icon
67
Century Therapeutics
IPSC
$370M
$4.5M 0.16%
1,355,000
+256,500
+23% +$467K
SCYX icon
68
SCYNEXIS
SCYX
$36M
$3.23M 0.12%
181,091
+16,160
+10% +$237K
CMPX icon
69
Compass Therapeutics
CMPX
$367M
$2.5M 0.09%
1,599,600
– –
RVMD icon
70
Revolution Medicines
RVMD
$39.1B
$1.72M 0.06%
60,000
-597,200
-91% -$14.4M
HYPR icon
71
Hyperfine
HYPR
$90.9M
$1.33M 0.05%
1,188,178
– –
AMLX icon
72
Amylyx Pharmaceuticals
AMLX
$2.17B
$949K 0.03%
64,501
-1,692,439
-96% -$25.9M
CMAX
73
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$317K 0.01%
21,200
– –
NUVB.WS
74
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$5.37K ﹤0.01%
89,543
– –
ALT icon
75
Altimmune
ALT
$581M
– –
-1,159,900
Closed -$3.02M
1 2
3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2023 Portfolio in Review

As of Q4 2023, Avidity Partners Management held 95 positions worth $2.74B, up 11% from $2.48B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $140M in Q4 2023, closing 21 positions and reducing 31 holdings. Its most notable exit was Cigna, an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Thermo Fisher Scientific worth $96.9M.

  • Avidity Partners Management's largest Q4 2023 buy was Thermo Fisher Scientific: 182,600 shares worth $96.9M.
  • Avidity Partners Management added most to Structure Therapeutics in Q4 2023, an estimated $33.2M increase.
  • Avidity Partners Management's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $38.5M.
  • Avidity Partners Management fully exited Cigna in Q4 2023, selling an estimated $60.7M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.74B portfolio in Q4 2023.
  • Avidity Partners Management opened 12 new positions and closed 21 in Q4 2023.
  • Avidity Partners Management's portfolio value rose 11% quarter-over-quarter to $2.74B.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.